New pill targets Hard-to-Treat lung cancer mutations
Disease control
Recruiting now
This study tests an experimental oral drug called VRN110755 in people with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer). The drug is designed to block cancer growth by targeting the EGFR protein and certain resistance mutations, including C797S. The tri…
Phase: PHASE1, PHASE2 • Sponsor: Voronoi, Inc • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC